The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Transcatheter tricuspid valve treatment: does annular reduction make a difference?

EuroIntervention 2021;16:e1213-e1214. DOI: 10.4244/EIJV16I15A219

1. Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland


Growing evidence supports the association between severe tricuspid regurgitation (TR) and poor cardiovascular outcomes. Patients with relevant TR are more frequently hospitalised and have a higher cardiovascular mortality compared to those with no or mild regurgitation1. Surgery is rarely performed for the treatment of isolated severe TR owing to the high in-hospital mortality (close to 10%) reported even in contemporary series2.

The correlation between TR and prognosis appears to go beyond the usually accepted definition of severe TR. There may be a continuous rise of the risk of death with increasing effective regurgitant orifice area (EROA)3. In contrast to ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Coronary interventions in 2020: the year in review